Organoid Models

HUB Organoid Technology offers the most relevant in vitro pre-clinical models for efficacy screening of drugs against several human diseases, such cancer or cystic fibrosis. The unique capacity of HUB Organoids to recapitulate characteristics of the organ they are originated from, opens new possibilities for research and drug development. Moreover, the long-term expansion of HUB Organoid cultures and the access to healthy counterpart, provides a unique platform for drug discovery and development.

Cystic Fibrosis models Description

Cystic fibrosis (CF) is an inherited disorder that causes severe damage to the lungs, digestive system and other organs in the body. People with CF carry a defect in CFTR gene causing the body secretions to become sticky and thick, impeding the functionality of the organs affected.

Worldwide, about 70,000 to 100,000 people have CF. A major problem in treating CF is the diversity of the genetic defect. More than 2000 different mutations have been identified in CF patients, and while 12 mutations are represented in 50% of the CF population, more than 1900 mutations are distributed in the other 50%.

HUB has demonstrated with an assay developed by its founders that we can determine the clinical response (or lack of response) of patients directly on an organoid of that patient. In addition, HUB has generated a CF biobank (Hyperlink to HUB catalogue) that consist of more than 400 organoid cultures derived from rectal biopsies of CF patients and representing more than 100 mutations, both common and rare mutations. Using this CF Biobank the effectiveness of (novel) compounds on the CF population or specific mutations can accurately determined in vitro (Forskolin-induced swelling (FIS) assay) (a hyperlink in these words should direct to the definition of the Assay)

Cancer models Description

Organoids can be established directly from biopsies or resections of cancer with very high efficiency. Therefore, we can generate a genetically stable, heterogeneous, and patient relevant biobank of all carcinoma indications (table 1). In addition, organoids can be established from both normal and malignant tissues of patients. Using the platform highly relevant and efficient drug screening and development for oncological drugs can be performed in an in vitro model that represents the heterogenic mutational landscape present in cancer patients.

HUB offers a unique collection of well characterized cancer organoid models for industry’s in-house use, for drug testing at HUB or its partners.

Immuno-oncology models Description

HUB has established a new organoid model to co-cultures patient-derived tumour organoids and immune cells, either innate or engineered, for the screening of IO compounds, or engineered T-cells.


Toxicology models Description

Pre-clinical assessment of newly developed drugs is out of utmost importance to predict their safety and efficacy in humans. HUB has established organoid cultures from pre-clinical animal modes such as rat, dog, minipig and monkey. These organoid cultures are generated from several gastrointestinal track regions and faithfully recapitulate the original tissue response to external stimuli. Furthermore, HUB has validated the use of organoid cultures derived from human donors as liver toxicology model.

HUB toxicology organoid models represent a unique in vitro platform to study toxicity, absorption, metabolism and pharmacokinetics of compounds, drugs safety and efficacy allowing decision making at early stage of drug development.

Infectious disease models Description

HUB healthy organoids represent all components of tissue derived and are suited to study infectious diseases affecting specialized human cell types, such respiratory syncytial virus (RSV) on human lung organoids or hepatitis B virus (HBV) in human liver organoids.

Other indications Description

HUB and various industry partners collaborate to continuously develop new Organoid models. Currently we are setting up models for COPD, and other (genetic) lung diseases, IBD, genetic liver diseases. Upon your request we can discuss if an organ or disease can be represented and developed as an Organoid model.